| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Prognostic significance of autoimmunity during treatment of melanoma with interferon. | N Engl J Med | 2006 | 4.47 |
| 2 | Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. | J Clin Oncol | 2009 | 2.63 |
| 3 | Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. | J Transl Med | 2010 | 0.85 |
| 4 | The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. | Melanoma Res | 2004 | 0.82 |
| 5 | Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study. | Anticancer Res | 2004 | 0.81 |